Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base
Included In Small-Cell Lung Cancer Guidelines In US For Second-Line Use
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
